These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31290664)

  • 1. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
    Huang D; Gaul DA; Nan H; Kim J; Fernández FM
    J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
    Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
    J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.
    Kim J; Coffey DM; Ma L; Matzuk MM
    Endocrinology; 2015 Jun; 156(6):1975-81. PubMed ID: 25815421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of ovarian cancer cell secretome during epithelial to mesenchymal transition reveals a protein signature associated with advanced stages of ovarian tumors.
    Lanfredi GP; Thomé CH; Ferreira GA; Silvestrini VC; Masson AP; Vargas AP; Grassi ML; Poersch A; Candido Dos Reis FJ; Faça VM
    Biochim Biophys Acta Proteins Proteom; 2021 Jun; 1869(6):140623. PubMed ID: 33607274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine Learning Reveals Lipidome Remodeling Dynamics in a Mouse Model of Ovarian Cancer.
    Bifarin OO; Sah S; Gaul DA; Moore SG; Chen R; Palaniappan M; Kim J; Matzuk MM; Fernández FM
    J Proteome Res; 2023 Jun; 22(6):2092-2108. PubMed ID: 37220064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks.
    Zhang X; Chen L; Liu Y; Xu Y; Zhang X; Shi Y; Wang C; Zhang PL; Liu Y
    Cytopathology; 2018 Jun; 29(3):247-253. PubMed ID: 29280203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
    Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
    Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
    Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
    Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.
    Medrano M; Communal L; Brown KR; Iwanicki M; Normand J; Paterson J; Sircoulomb F; Krzyzanowski P; Novak M; Doodnauth SA; Saiz FS; Cullis J; Al-Awar R; Neel BG; McPherson J; Drapkin R; Ailles L; Mes-Massons AM; Rottapel R
    Cell Rep; 2017 Mar; 18(10):2343-2358. PubMed ID: 28273451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model.
    Sah S; Ma X; Botros A; Gaul DA; Yun SR; Park EY; Kim O; Moore SG; Kim J; Fernández FM
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.
    Hu Y; Pan J; Shah P; Ao M; Thomas SN; Liu Y; Chen L; Schnaubelt M; Clark DJ; Rodriguez H; Boja ES; Hiltke T; Kinsinger CR; Rodland KD; Li QK; Qian J; Zhang Z; Chan DW; Zhang H;
    Cell Rep; 2020 Oct; 33(3):108276. PubMed ID: 33086064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
    Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
    Kobayashi H; Ogawa K; Kawahara N; Iwai K; Niiro E; Morioka S; Yamada Y
    Free Radic Res; 2017 Oct; 51(9-10):755-764. PubMed ID: 28931330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
    Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
    Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
    Harrington BS; He Y; Davies CM; Wallace SJ; Adams MN; Beaven EA; Roche DK; Kennedy C; Chetty NP; Crandon AJ; Flatley C; Oliveira NB; Shannon CM; deFazio A; Tinker AV; Gilks CB; Gabrielli B; Brennan DJ; Coward JI; Armes JE; Perrin LC; Hooper JD
    Br J Cancer; 2016 Feb; 114(4):417-26. PubMed ID: 26882065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.